Povorcitinib

• Description :

  Povorcitinib (INCB54707) is a potent and selective JAK1 inhibitor that effectively reduces abscesses and inflammatory nodules. Povorcitinib is used to study cutaneous lupus erythematosus (CLE) and lichen planus (LP) [1][2].

• Product Name Alternative :

  INCB54707

• UNSPSC :

  12352005

• Target :

  JAK

• Type :

  Reference compound

• Related Pathways :

  Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Inflammation/Immunology

• Assay Protocol :

  https://www.medchemexpress.com/povorcitinib.html

• Purity :

  99.00

• Solubility :

  DMSO : 250 mg/mL (ultrasonic)

• Smiles :

  N#CCC1(N2C=C(C3=C(C)NN=C3C)C=N2)CN(C4=C(C=C(C(F)=C4)C(N[C@@H](C)C(F)(F)F)=O)F)C1

• Molecular Formula :

  C23H22F5N7O

• Molecular Weight :

  507.46

• References & Citations :

  [1]Paul Smith, et al. Use of jak1 inhibitors for the treatment of cutaneous lupus erythematosus and lichen planus (lp) . Patent WO2021076124A1.|[2]Kirby JS, et al. Efficacy and safety of the oral Janus kinase 1 inhibitor povorcitinib (INCB054707) in patients with hidradenitis suppurativa in a phase 2, randomized, double-blind, dose-ranging, placebo-controlled study. J Am Acad Dermatol. 2023 Oct 21:S0190-9622 (23) 03037-2.|[3]Zouboulis C C, et al. European S2k guidelines for hidradenitis suppurativa/acne inversa part 2: Treatment[J]. Journal of the European Academy of Dermatology and Venereology, 2024.|[4]Tuttle KD, et al., JAK1 Inhibition Blocks Lethal Immune Hypersensitivity in a Mouse Model of Down Syndrome. Cell Rep. 2020 Nov 17;33 (7) :108407.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Phase 3

• CAS Number :

  [1637677-22-5]